Fulgent Genetics, Inc. (FLGT)
Nasdaq · Healthcare · Diagnostics & Research
$22.45+4.52%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $618M
- 52-week range
- $13.46 – $31.04
- 52-week change
- −5.08%
- EPS (trailing)
- −$2.94
- Next earnings
- Nov 6, 2026
Fiscal year to Dec 2025
- Revenue
- $323M (+13.83%)
- Net income
- −$60.5M
- Operating margin
- −28.2%
- Free cash flow
- −$124M
From the company’s annual report on SEC EDGAR.
About Fulgent Genetics, Inc.
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA.
Headquarters: El Monte, United States · 1,315 employees · fulgentgenetics.com